AstraZeneca Stock Price, News & Analysis (NYSE:AZN)

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca declared a semiannual dividend on Friday, February 15th. Shareholders of record on Friday, March 1st will be given a dividend of $0.95 per share on Wednesday, March 27th. This represents a yield of 4.64%. The ex-dividend date is Thursday, February 28th. This is a boost from AstraZeneca's previous semiannual dividend of $0.45. View AstraZeneca's Dividend History.

AstraZeneca's stock split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

AstraZeneca plc (NYSE:AZN) issued its earnings results on Thursday, July, 25th. The company reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of $0.30 by $0.43. The company had revenue of $5.72 billion for the quarter, compared to analyst estimates of $5.57 billion. AstraZeneca had a net margin of 9.38% and a return on equity of 35.83%. The firm's revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.69 earnings per share. View AstraZeneca's Earnings History.

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, October 24th 2019. View Earnings Estimates for AstraZeneca.

AstraZeneca will be holding an earnings conference call on Thursday, October 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AstraZeneca updated its FY19 earnings guidance on Thursday, July, 25th. The company provided EPS guidance of $3.50-3.70 for the period, compared to the Thomson Reuters consensus estimate of $3.54.

19 equities research analysts have issued 1 year price objectives for AstraZeneca's stock. Their predictions range from $40.73 to $50.00. On average, they expect AstraZeneca's share price to reach $46.12 in the next year. This suggests a possible upside of 3.2% from the stock's current price. View Analyst Price Targets for AstraZeneca.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 4 sell ratings, 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AstraZeneca.

News coverage about AZN stock has been trending somewhat positive this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AstraZeneca earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for AstraZeneca.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include AT&T (T), Pfizer (PFE), AbbVie (ABBV), Bank of America (BAC), Cisco Systems (CSCO), Gilead Sciences (GILD), Merck & Co., Inc. (MRK), Micron Technology (MU), Intel (INTC) and Netflix (NFLX).

AstraZeneca's stock is owned by many different of retail and institutional investors. Top institutional investors include ZWJ Investment Counsel Inc. (0.03%), CIBC Private Wealth Group LLC (0.02%), Envestnet Asset Management Inc. (0.02%), Vigilant Capital Management LLC (0.01%), Park National Corp OH (0.01%) and CWM LLC (0.01%). View Institutional Ownership Trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Stephens Inc. AR, Gradient Investments LLC, BLB&B Advisors LLC, World Asset Management Inc, Town & Country Bank & Trust CO dba First Bankers Trust CO, TIAA FSB and Tealwood Asset Management Inc.. View Insider Buying and Selling for AstraZeneca.

AZN stock was purchased by a variety of institutional investors in the last quarter, including CWM LLC, Park National Corp OH, Envestnet Asset Management Inc., Bailard Inc., CHURCHILL MANAGEMENT Corp, Vigilant Capital Management LLC, Essex Investment Management Co. LLC and ZWJ Investment Counsel Inc.. View Insider Buying and Selling for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $44.69.

AstraZeneca has a market capitalization of $117.26 billion and generates $22.09 billion in revenue each year. The company earns $2.16 billion in net income (profit) each year or $1.73 on an earnings per share basis. AstraZeneca employs 64,400 workers across the globe.View Additional Information About AstraZeneca.

The official website for AstraZeneca is http://www.astrazeneca.com/.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]